New pill hopes to calm Crohn's Flare-Ups
NCT ID NCT07403968
First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 2 times
Summary
This early-stage study tests a new drug called zasocitinib (TAK-279) in 20 adults with active Crohn's disease who have not responded to other treatments. The main goal is to see if the drug is safe and how it affects inflammation in the gut. Participants will take the drug for 12 weeks and undergo a colonoscopy to check for changes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CROHN'S DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- AI reads scans to forecast Crohn's complications
- Can stem cell vesicles heal Crohn's fistulas?
- Can a new drug calm the Gut's overactive immune response in Crohn's?
- Can a new drug keep Crohn's disease in check?
- Can a biologic drug tame Crohn's without steroids? a large Real-World study investigates
- Can a glass of pomegranate juice tame gut inflammation?